Pain relief and improved functional scores (reduced limp, easier stair climbing, longer walking tolerance) occur in 60–75% of treated participants within 3–6 months. Radiographic cartilage thickening or preservation of joint space is observed in approximately 40–50% of cases on follow-up imaging. Successful outcomes are more common in early-stage OA (Kellgren-Lawrence grade 2) than in severe disease.
Twelve completed trials and 3 actively recruiting trials are registered for hip osteoarthritis cell therapy, predominantly using placental MSC or chondrocyte injection into the hip joint under fluoroscopic guidance. Trial cohorts span mild-to-moderate radiographic OA (Kellgren-Lawrence grades 2–3) and include both primary OA and post-traumatic arthritis. Cartilage imaging by MRI has shown improved signal intensity (suggesting rehydrated cartilage matrix) in 40–60% of treated hips at 12 months. Pain scores and functional metrics (6-minute walk distance, Harris Hip Score) improve modestly in 55–75% of participants over 6–24 months, though comparative data versus placebo injection are sparse.
Sunt un candidat? → · Hip Osteoarthritis: full overview → · Cost Artroza de Șold → · Cost →
Revizuit medical de echipa editorială a StemCellAtlas cu Dr Tymur Lukyanenko (Orthopaedic Traumatologist · 20+ yrs clinical, 15+ yrs cell therapy) ale clinicii partenere Stem Plus (Sofia), în funcție de orientările ISSCR, FDA și EMA. Educational information, not medical advice; figures indicative.
Medicină regenerativă certificată GMP în inima UE — de la 3.000–8.000 €, o fracțiune din prețurile din SUA sau Germania. Protocoale personalizate pentru pacienți din peste 50 de țări.
Evaluare medicală gratuită